Published in
Taylor and Francis Group, Leukemia & Lymphoma, 11(58), p. 2633-2641, 2017
DOI: 10.1080/10428194.2017.1306648
Links
Tools
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients
Journal article published in 2017 by
Giovanni D’Arena 
,
Vittorio Simeon,
Luca Laurenti,
Michele Cimminiello,
Idanna Innocenti,
Michele Gilio ,
Angela Padula,
Maria Luigia Vigliotti,
Sonya De Lorenzo,
Giacomo Loseto,
Anna Passarelli,
Matteo Nicola Dario Di Minno ,
Marco Tucci,
Vincenzo De Feo,
Fiorella D’Auria
and other authors.
,
Vittorio Simeon,
Luca Laurenti,
Michele Cimminiello,
Idanna Innocenti,
Michele Gilio ,
Angela Padula,
Maria Luigia Vigliotti,
Sonya De Lorenzo,
Giacomo Loseto,
Anna Passarelli,
Matteo Nicola Dario Di Minno ,
Marco Tucci,
Vincenzo De Feo,
Fiorella D’Auria
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 